| Bioactivity | TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC50: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model[1]. |
| Target | 3.15 μM (BACE1). |
| Name | TAK-070 Free base |
| CAS | 212571-56-7 |
| Formula | C27H31NO |
| Molar Mass | 385.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fukumoto H, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66. |
TAK-070 Free base
CAS: 212571-56-7 F: C27H31NO W: 385.54
TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC50: 3.15 μM). TAK-070 Free base can be used
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.